ClinicalTrials.gg
CompletedNCT00384839Updated Oct 25, 2018Results posted

Vidaza to Restore Hormone Thx Prostate

A Phase 2 interventional study of azacitidine for injectable suspension in Prostate Cancer, sponsored by US Oncology Research. Completed at 13 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-25.

Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
1,758th of 3,023
36 · median 48
Started
2006
with 130 others
Phase 2
1,063 of 3,596
145 open now
Registered
553rd of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 1,758th largest by enrollment of the 3,023 interventional ones that give a count, is one of 131 that started in 2006, is one of 1,063 in phase 2, and was the 553rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to find out what effects (good and bad) Vidaza has on patients with prostate cancer. This investigational drug is not approved by the Food and Drug Administration (FDA) for the treatment of prostate cancer; however, it is approved in myelodysplastic syndrome - a bone marrow disease. The pharmaceutical company involved in this study, Pharmion Corporation, is the manufacturer of Vidaza.

Read the detailed description

This is an open label Phase II study. Patients will receive Vidaza for 5 consecutive days (Days 1- 5) of each 28-day cycle. Complete androgen ablation will be continued. Response will be assessed after a minimum of 2 cycles (evaluable patients). PSA response will be evaluated prior to each cycle and % fetal hemoglobin will be evaluated prior to each odd cycle (excluding Cycle 1). Patients will be treated until clinical progression up to a maximum of 12 cycles. A total of 35 patients with advanced metastatic HRPC will be enrolled in this trial.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of confirmed, progressive, advanced , or nonmetastatic prostate cancer with documented PSA progression, with a calculated PSA doubling time \<3 months, on complete androgen ablation therapy. PSA progression, with or without clinical progression (symptomatic/radiologic as per ) is required; is not required.

Baseline PSA values must be followed by 2 serial increases at least 2 weeks apart (no upper limit for time for these 2 samples). Calculated PSA doubling time, for the above PSA values must be \<3 months. An automated PSA doubling time calculator may be found at www.mskcc.org/mskcc/html/10088.cfm (see study tools).

  • Currently on complete androgen ablation hormone therapy (an LHRH agonist plus an antiandrogen) with testosterone level \<50ng/dL). Patients who are on LHRH agonist or other antiandrogenic therapy at entry will continue that therapy while on this study. Anti-androgen withdrawal is not necessary and is precluded before enrollment on the trial. The details of that therapy must be recorded in the CRF. Patients who have had an orchiectomy and who are on antiandrogen therapy are permitted on study.
  • An elevated PSA level for patients progressing by PSA criteria is required (see protocol for specific detail).
  • Has a Performance Status >70
  • Is greater than 18 years of age
  • Must meet specific lab values for the following criteria: granulocyte, count, total , and ALT, serum creatinine, calculated \& urinalysis (see protocol for specific detail).
  • If fertile, the patient has agreed to use an acceptable method of to avoid fathering a child for the duration of the study and for a period of 2 months thereafter.
  • Has signed a Patient Form
  • Has signed a Patient Authorization Form

Exclusion criteria

EXCLUSION CRITERIA:

  • Has only clinical progression without evidence of PSA progression
  • Has received prior chemotherapy
  • Has had prior treatment with Vidaza
  • Has a history of to any component of Vidaza (mannitol)
  • Has a history of (NYHA) heart disease Class III or IV (Appendix III) or myocardial infarction within 6 months prior to Day 1 or unstable arrhythmia or evidence of ischemia on (ECG)
  • Is receiving concurrent immunotherapy
  • Is receiving concurrent bisphosphonate therapy; long-standing bisphosphonate therapy (initiated >8 weeks prior to registration) is acceptable. Bisphosphonates started within the prior 8 weeks will not be allowed since this may affect other study endpoints and render their interpretation difficult.
  • Has received treatment with radiation therapy, surgery, chemotherapy, ketoconazole, , or an agent within 1 month prior to registration, (6 weeks for radiation therapy, nitrosureas or Mitomycin C)
  • Has evidence of central nervous system (CNS) involvement
  • Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection that requires systemic therapy
  • Has a serious uncontrolled nonmalignant disease (liver failure, or other condition) that could compromise protocol objectives in the opinion of the Investigator
  • Has a history of other within the last 5 years (except cured basal cell carcinoma of skin), which could affect the diagnosis or assessment of any of the study drugs
  • Is known to be positive for the (HIV), , or
  • Is unable to comply with requirements of study
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    1

    azacitidine for injectable suspension

    Drug: azacitidine for injectable suspension

Interventions

  • Vidaza: 75 mg/m2 for 5 consecutive days (Days 1-5) of each 28 day cycle. A cycle will equal to 28 days. Patient will receive a maximum of 12 cycles.

    Also known as: Vidaza™

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With PSA Doubling Time >=3 Months.

    To determine if Vidaza can convert hormone-refractory prostate cancer to a hormone-responsive state. This will be assessed by the proportion of patients who have a documented prostate specific antigen (PSA) doubling time \>3= months.

    Time frame: Until progression or up to a maximum of 12 cycles

Secondary outcomes

  1. PSA Response Rate

    Complete PSA Response defined as complete normalization of PSA maintained for at least 4 weeks, and partial PSA response defined as a decrease in PSA level of at least 50% from baseline level maintained for at least 4 weeks.

    Time frame: Every 8 weeks for 1 year.

  2. Objective Response Rate by Recist (ORR)

    ORR = Complete Response (CR) + Parcial response (PR). CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

    Time frame: Every 8 weeks for 1 year.

  3. Progression-free Survival

    PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Up to 1.5 year.

  4. 1-year Overall Survival (OS)

    OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

    Time frame: Up to 1 year.

  5. Changes in Fetal Hemoglobin (HbF) With Time.

    Time from baseline to maximal fetal hemoglobin (HbF).

    Time frame: Up to 1 year.

07

Results

Posted Oct 25, 2018
Limitations and caveats
Further development of azacitidine in patients with prostate cancer may be warranted in randomized trials, alone and in combination with hormonal therapy, chemotherapy and histone deacytelase inhibitors

Participant flow

Participant flow — Overall Study
MilestoneVidaza
Started36
Completed28
Not completed8
Withdrew: Adverse event4
Withdrew: Investigator request1
Withdrew: Patient request1
Withdrew: Ineligible2

Outcome measures

PrimaryPercentage of Patients With PSA Doubling Time >=3 Months.

To determine if Vidaza can convert hormone-refractory prostate cancer to a hormone-responsive state. This will be assessed by the proportion of patients who have a documented prostate specific antigen (PSA) doubling time \>3= months.

Time frame:
Until progression or up to a maximum of 12 cycles
Reported as:
Number · % of patients with PSA-DT>= 3 months
Percentage of Patients With PSA Doubling Time >=3 Months.
% of patients with PSA-DT>= 3 monthsVidaza
Percentage of Patients With PSA Doubling Time >=3 Months.55.8 (37.9 to 72.8)
SecondaryPSA Response Rate

Complete PSA Response defined as complete normalization of PSA maintained for at least 4 weeks, and partial PSA response defined as a decrease in PSA level of at least 50% from baseline level maintained for at least 4 weeks.

Time frame:
Every 8 weeks for 1 year.
Reported as:
Number · percentage of participants
PSA Response Rate
percentage of participantsVidaza
PSA Response Rate0 (0 to 0)
SecondaryObjective Response Rate by Recist (ORR)

ORR = Complete Response (CR) + Parcial response (PR). CR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

Time frame:
Every 8 weeks for 1 year.
Reported as:
Number · percentage of participants
Objective Response Rate by Recist (ORR)
percentage of participantsVidaza
Objective Response Rate by Recist (ORR)0 (0 to 0)
SecondaryProgression-free Survival

PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
Up to 1.5 year.
Reported as:
Median · weeks
Progression-free Survival
weeksVidaza
Progression-free Survival12.4 (2.1 to 70.3)
Secondary1-year Overall Survival (OS)

OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

Time frame:
Up to 1 year.
Reported as:
Number · Probability of Survival at 1-year
1-year Overall Survival (OS)
Probability of Survival at 1-yearVidaza
1-year Overall Survival (OS)0.73 (0.54 to 0.85)
SecondaryChanges in Fetal Hemoglobin (HbF) With Time.

Time from baseline to maximal fetal hemoglobin (HbF).

Time frame:
Up to 1 year.
Reported as:
Median · weeks
Changes in Fetal Hemoglobin (HbF) With Time.
weeksVidaza
Changes in Fetal Hemoglobin (HbF) With Time.12.7 (8.4 to 26.6)

Adverse events

Collected over During the whole treatment period, up to 30 days following last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vidaza—1/34 (2.9%)31/34 (91.2%)
Most frequent serious events
Most frequent serious events
EventVidaza
NAUSEAGastrointestinal disorders1/34
VOMITINGGastrointestinal disorders1/34
Most frequent other events
Showing 10 of 17
Most frequent other events
EventVidaza
FATIGUEGeneral disorders14/34
CONSTIPATIONGastrointestinal disorders13/34
NAUSEAGastrointestinal disorders11/34
VOMITINGGastrointestinal disorders10/34
INJECTION SITE REACTIONSkin and subcutaneous tissue disorders9/34
ANEMIABlood and lymphatic system disorders7/34
ANOREXIAGastrointestinal disorders7/34
NEUTROPENIABlood and lymphatic system disorders6/34
DIARRHEAGastrointestinal disorders3/34
LEUCOPENIABlood and lymphatic system disorders3/34

Baseline characteristics

ITT Population

Age, Continuous
Age, Continuous(years)Vidaza
Mean71.1 ± 9.19
Sex: Female, Male
Sex: Female, Male(Participants)Vidaza
Female0
Male36
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Vidaza
Caucasian33
Hispanic2
Black1
Region of Enrollment
Region of Enrollment(participants)Vidaza
United States36
08

Study locations

13 sites
  • Rocky Mountain Cancer Center-Midtown
    Denver, Colorado 80218, United States
  • Cancer Centers of Florida, P.A.
    Ocoee, Florida 34761, United States
  • Minnesota Oncology Hematology, P.A.
    Minneapolis, Minnesota 55404, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89109, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12208, United States
  • Raleigh Hematology Oncology Associates
    Cary, North Carolina 27511, United States
  • Northwestern Carolina Oncology Hematology
    Hickory, North Carolina 28602, United States
  • Texas Oncology, P.A.
    Dallas, Texas 75246, United States
  • Texas Oncology, P.A.
    Fort Worth, Texas 76104, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Deke Slayton Cancer Center
    Webster, Texas 77598, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Cancer Care Nrothwest-South
    Spokane, Washington 99202, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 8 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2006
First posted
Oct 6, 2006
Start
Apr 2006
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results first posted
Oct 25, 2018
Last update
Oct 25, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00384839
Responsible party
Sponsor
First posted
Oct 6, 2006
Start date
Apr 2006
Primary completion
Nov 2009
Completion
Nov 2009
Results posted
Oct 25, 2018
Last update
Oct 25, 2018

Study contacts

Guru Sonpavde, MD
principal investigator · US Oncology Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion